Pep-1-Phor21

Pep-1-Phor21 is a synthetic hybrid lytic peptide designed for the targeted treatment of cancers that overexpress the Interleukin-13 receptor alpha 2 (IL-13Rα2), such as prostate cancer. The molecule is a fusion construct consisting of two functional domains: Pep-1, a peptide ligand that specifically binds to the IL-13Rα2 cell surface receptor, and Phor21, a synthetic lytic peptide known for its ability to disrupt cell membranes. The mechanism of action involves the selective binding of the Pep-1 moiety to the target receptor on cancer cells, which brings the Phor21 lytic domain into close proximity with the plasma membrane. This leads to membrane disintegration and rapid cell death (cytolysis). Preclinical research has demonstrated that the cytotoxic potency of Pep-1-Phor21 is directly correlated with the expression levels of IL-13Rα2, and its efficacy can be further enhanced by using epigenetic regulators like Trichostatin A or 5-aza-2 deoxycytidine to upregulate receptor expression in low-expressing cells.

Other names

hybrid lytic peptidePep-1-Phor21 peptidePep1-Phor21 peptidePep 1-Phor21 peptide